

CORRECTION

Open Access



# Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study

Kosuke Ebina<sup>1\*</sup>, Motomu Hashimoto<sup>2</sup>, Wataru Yamamoto<sup>2,3</sup>, Toru Hirano<sup>4</sup>, Ryota Hara<sup>5</sup>, Masaki Katayama<sup>6</sup>, Akira Onishi<sup>7</sup>, Koji Nagai<sup>8</sup>, Yonsu Son<sup>9</sup>, Hideki Amuro<sup>9</sup>, Keiichi Yamamoto<sup>10</sup>, Yuichi Maeda<sup>4</sup>, Koichi Murata<sup>2</sup>, Sadao Jinno<sup>7</sup>, Tohru Takeuchi<sup>8</sup>, Makoto Hirao<sup>1</sup>, Atsushi Kumanogoh<sup>4</sup> and Hideki Yoshikawa<sup>1</sup>

## Correction to: *Arthritis Res Ther*

<https://doi.org/10.1186/s13075-019-1880-4>

Following publication of the original article [1], the authors noticed that two corrections were not implemented during the production process. The original article [1] has been corrected.

In Fig. 1b, the heading should read: Adjusted survival due to lack of effectiveness

In Fig. 2b, the heading should read: Adjusted survival due to toxic adverse events

In addition, the authors would like to update the legends of Figure 1, 2, 3 and 4 to the following:

Fig. 1 Drug survival rates due to lack of effectiveness in **a** non-adjusted cases and **b** adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 2 Drug survival rates due to toxic adverse events in **a** non-adjusted cases and **b** adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN =

etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 3 Drug survival rates due to remission in **a** non-adjusted cases and **b** adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 4 Overall drug survival rates (excluding non-toxic reasons and remission) in **a** non-adjusted cases and **b** adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

The publishers apologise for the errors. The corrected figures are given below:

\* Correspondence: [k-ebina@umin.ac.jp](mailto:k-ebina@umin.ac.jp)

<sup>1</sup>Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan

Full list of author information is available at the end of the article



**Author details**

<sup>1</sup>Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan. <sup>2</sup>Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan. <sup>3</sup>Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan. <sup>4</sup>Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan. <sup>5</sup>The Center for Rheumatic Diseases, Nara Medical University, Nara, Japan. <sup>6</sup>Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan. <sup>7</sup>Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan. <sup>8</sup>Department of Internal Medicine (IV), Osaka Medical College, Osaka, Japan. <sup>9</sup>First Department of Internal Medicine, Kansai Medical University, Osaka, Japan. <sup>10</sup>Department of Medical Informatics, Wakayama Medical University Hospital, Wakayama, Japan.

Received: 15 April 2019 Accepted: 15 April 2019

Published online: 06 May 2019

**Reference**

1. Ebina, et al. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study. *Arthritis Res Ther.* 2019;21:91 <https://doi.org/10.1186/s13075-019-1880-4>.



